Galactoarabino-rhamnogalacturonate: Phase IIa data

Top-line data from the double-blind, U.S. Phase IIa NASH- FX trial in 30 patients with NASH with advanced hepatic fibrosis showed that 8 mg/kg GR-MD-02 every 2 weeks missed the primary endpoint of imp...